Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension

Author profile image Aggregator
0 comments
Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

Source: NeurologyLive Published 04 Nov 2026 Imported 04 Nov 2026 Relevancy: Not reviewed

Read the article